RIO Trial Finds Broadly Neutralizing Antibodies Delay HIV Viral Rebound After Treatment Interruption

For people living with HIV, modern antiretroviral therapy can drive the virus down to undetectable levels and keep it there for decades. What it cannot do is erase the reservoir of latently infected cells that persists quietly in the body. That reservoir is why treatment must continue for life, and it is the single biggest obstacle separating today's standard of care from a functional cure. One of the most closely watched strategies for attacking that reservoir involves broadly neutralizing antibodies — laboratory-derived immune proteins engineered to recognize a wide spectrum of HIV strains. New results from the phase II randomized controlled RIO trial, published in Nature Medicine on 15 September 2026, offer a detailed look at how one antibody-based approach performed when participants paused their routine treatment.

Why Antibodies Enter the HIV Cure Conversation

Broadly neutralizing antibodies, often shortened to bNAbs, work differently from antiretroviral drugs. Instead of targeting viral enzymes inside infected cells, they bind to exposed regions of the HIV envelope protein and flag the virus for destruction by the immune system. Because they are antibodies rather than small molecules, they can also recruit other immune functions, potentially helping the body recognize and clear infected cells that drugs alone leave untouched.

The appeal for cure research is twofold. First, a single antibody infusion can remain active in the bloodstream for weeks or months, raising the possibility of long-acting regimens that do not depend on daily pills. Second, and more ambitiously, bNAbs might help keep the virus suppressed during a deliberate treatment pause, buying the immune system time to mount a stronger response or allowing researchers to measure how much of the reservoir is genuinely capable of reigniting infection.

Inside the RIO Trial Design

The RIO trial was built as a phase II randomized controlled study, a stage of clinical research designed to measure biological effect and safety rather than to confirm large-scale efficacy. The newly reported results focus specifically on secondary and exploratory outcomes — the endpoints that sit alongside a trial's primary analysis and often reveal how a treatment behaves in finer detail.

The population studied is notable: adult males living with HIV who agreed to undergo analytical treatment interruption, or ATI.

The Logic of Analytical Treatment Interruption

ATI is an intentional, closely supervised pause in antiretroviral therapy. It is not a treatment strategy offered in routine care. Instead, it is a research tool used to answer a question that suppressed viral loads cannot answer on their own: how much replication-competent virus remains, and how aggressively it returns once drug pressure is removed?

During an interruption, participants are monitored intensively, and treatment is restarted according to predefined rules — typically as soon as viral load crosses a set threshold or begins to climb consistently. The timing of that rebound becomes the measurement of interest. A longer delay suggests the intervention is holding the virus back; a rapid rebound suggests the reservoir remained fully capable of rebounding unimpeded.

What Randomized Control Adds

Because RIO was randomized and controlled, participants were allocated to different study arms rather than all receiving the same regimen. That structure allows investigators to compare outcomes between groups and to separate the effect of the antibody intervention from the natural variability of viral rebound, which differs widely between individuals. Secondary and exploratory analyses in such a design typically examine the kinetics of rebound, the emergence of viral variants, immune correlates, and safety signals over the follow-up period.

What the Reported Outcomes Show

According to the published findings, two themes stand out from the trial's secondary and exploratory results:

• Delayed viral rebound. Participants in the antibody-treated setting did not experience the immediate return of detectable virus that ATI studies typically anticipate, indicating that the antibodies were exerting measurable pressure on the reservoir during the treatment pause.
• Emergence of resistance. Alongside that delay, the trial documented resistance to broadly neutralizing antibodies, with 3BNC117 specifically implicated. This suggests that under antibody pressure, viral populations can adapt in ways that erode the treatment's effectiveness.

The combination of these two findings is what makes the RIO results scientifically interesting rather than simply encouraging. A delay in rebound confirms that bNAbs are doing something meaningful in the absence of antiretroviral drugs. Resistance confirms that HIV retains its long-standing talent for evolving around whatever pressure is applied to it.

Resistance as the Central Challenge

Resistance to broadly neutralizing antibodies is not a surprise to researchers who study HIV. The virus generates enormous genetic diversity within a single host, and any single-target intervention creates selective pressure that favors variants able to escape. Antibody monotherapy — using one bNAb alone — has long been viewed as especially vulnerable to this problem, because escape may require only a small number of mutations in the targeted envelope region.

The RIO findings reinforce why the field has increasingly moved toward combinations of antibodies, and toward pairing antibodies with other immune-modulating or latency-targeting approaches. If one antibody can be evaded, stacking multiple antibodies that recognize distinct envelope sites raises the genetic barrier to escape. Documenting exactly when and how resistance appeared during ATI provides a roadmap for designing those combinations and for deciding which participants might benefit most.

What This Means for People Living With HIV

It is important to be clear about what a phase II secondary and exploratory analysis does and does not establish. These results do not indicate that broadly neutralizing antibodies are ready to replace antiretroviral therapy, nor that treatment interruption is safe outside a tightly controlled research protocol. ATI carries real risks, including viral load spikes, transmission risk, and decline in immune function, which is why it is conducted only with intensive monitoring and strict restart criteria.

What the RIO trial does contribute is mechanistic clarity. It shows that antibody-based intervention can shift the timing of viral rebound in adult males living with HIV, and it documents the resistance pathways that emerge when it does. Both pieces of information are essential for the iterative process of cure research: understanding what works, why it works, and precisely how it fails.

Open Questions Moving Forward

Several questions follow naturally from these outcomes. How durable is the delay in rebound across different antibody combinations and dosing intervals? Do participants who experience delayed rebound while on antibodies show any lasting change in reservoir size afterward? Can resistance be anticipated through pre-treatment viral sequencing, allowing regimens to be tailored to each person's dominant viral variants? And how do the dynamics observed in adult males extend to broader populations, including women and other groups not represented in this cohort?

The RIO trial does not answer all of these, but its secondary and exploratory findings give the field something concrete to build on: evidence that broadly neutralizing antibodies can hold HIV at bay for longer than expected during a treatment pause, paired with a candid accounting of the resistance that follows. In a research area where progress is measured in increments, that combination of promise and limitation is precisely the kind of data that shapes the next generation of trials.

This article is based on reporting by Nature Medicine. Read the original article.